Annovis Bio Granted U.S. Patent Covering New Crystalline Form of Buntanetap
Key Highlights
- ➤U.S. patent protects buntanetap Form B through June 21, 2044
- ➤Annovis completed enrollment in pivotal Phase 3 early Alzheimer’s trial
- ➤Symptomatic top-line Alzheimer’s data expected in Q1 2027
- ➤Disease-modifying Alzheimer’s readout expected in Q1 2028
Expert Statements
Maria Maccecchini, Founder, President and CEO of Annovis Bio
“Securing composition of matter protection for the new crystal form of buntanetap is an important milestone for Annovis”
Maria Maccecchini, Founder, President and CEO of Annovis Bio
“This patent covers the form of buntanetap (Form B) that we have moved into our clinical program, and it strengthens our position as we approach the readout of our pivotal Phase 3 Alzheimer’s study and prepare for regulatory submissions that will follow.”
* U.S. Patent No. 12,780,831 covers posiphen (buntanetap) D-tartrate Form B, a highly crystalline dihydrate, together with pharmaceutical compositions and methods of preparation, providing protection through 2044 * Form B is used in the Company’s ongoing pivotal Phase 3 trial in early Alzheimer’s disease and in the open-label extension Parkinson’s study * Issued patent strengthens the Company’s intellectual property position ahead of the top-line data readout from its fully enrolled pivotal Phase 3 Alzheimer’s trial MALVERN, Pa., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,780,831, titled “Solid Forms of Posiphen D-Tartrate.”
Get started
Create a free account to read the full story.